Chemical testing strategies for predicting health hazards to children

Reproductive Toxicology

Volumn 14, Issue 2, 2000, Pages 83-94

  Lamb IV, James C ^a   Brown, Shanna M ^b  

^a BBL Sciences   (United States)

^b Schwartz Connolly Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOXIC SUBSTANCE;

ANIMAL; ARTICLE; CARCINOGENICITY; CHEMICAL ANALYSIS; CHILD; CHRONIC TOXICITY; COST EFFECTIVENESS ANALYSIS; DANGEROUS GOODS; DOSE RESPONSE; ENVIRONMENTAL PROTECTION; EUROPEAN UNION; GENOTOXICITY; GOVERNMENT; HEALTH HAZARD; HUMAN; METHODOLOGY; MOUSE; NEUROPATHY; NEUROTOXICITY; PRACTICE GUIDELINE; PRESCHOOL CHILD; RAT; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; TOXICITY TESTING; UNITED STATES;

ANIMALIA;

EID: 0034122086     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(00)00059-9     Document Type: Note

References (84)

1. Juberg D.R., Kleinman C.F., Kwon S.C. Position paper of the American Council on Science and Health lead and human health . (Review) Ecotoxicology and Environmental Safety. 38:1997;162-180.
2. Goyer R.A. Nephrotoxicity and carcinogenicity of lead. Fundam Appl Toxicol. 18:1992;4-7.
3. Goyer R.A. Lead toxicity current concerns . Environ Health Perspect. 100:1993;177-187.
4. Goyer RA. Toxic effects of metals. In: Klaassen CD, editor. Toxicology: the basic science of poisons. 1996.
5. Preventing lead poisoning in young children a statement by the Centers for Disease Control and Prevention . 1991;CDC, Atlanta.
6. Plunkett L.M. Do current FIFRA testing guidelines protect infants and children? Lead as a case study. Regul Toxicol Pharmacol. 29:1999;80-87.
7. Curley A., et al. Dermal absorption of hexochlorophene in infants. Lancet. 7:1971;296-297.
8. Kimbrough R.D. Review of toxicology of hexachlorophene, including its neurotoxicity. J Clin Pharmacol. 13:1973;439-444.
9. Tyrala E.E., et al. Clinical pharmacology of hexachlorophene in newborn infants. J Pediatr. 91:1977;481-486.
10. Bressler R. Hexachlorophene in the newborn nursery. A risk-benefit analysis and review. Clin Pediatr (Phila). 16:1977;342-351.
11. West D.P., et al. Pharmacology and toxicology of infant skin. J Invest Dermatol. 76:1981;147-150.
12. Renwick A.G., Lazarus N.R. Human variability and noncancer risk assessment - An analysis of the default uncertainty factor. Regul Toxicol Pharmacol. 27:1998;3-20.
13. Pesticides in the diets of infants and children. 1993;National Academy Press, Washington, DC.
14. Environmental health criteria. 1986;WHO, Geneva.
15. Similarities and differences between children and adults implications for risk assessment . 1992;ISLI Press, Washington, DC.
16. Kimmel C.A. Developmental toxicity risk assessment consensus building, hypothesis, formulation, and focused research . Drug Metab Reviews. 28:1996;85-103.
17. Johnson E.M. Cross-species extrapolations and the biologic for safety factor determinations in developmental toxicology. Regul Toxicol Pharmacol. 8:1988;22-36.
18. Newman L.M., et al. Assessment of the effectiveness of animal developmental toxicity testing for human safety. Reprod Toxicol. 7:1993;359-390.
19. Guidelines for Developmental Toxicity Risk Assessment. Fed Reg. 56:1991;63798-63826.
20. Guidelines for reproductive toxicity risk assessment. 1996;EPA, Washington, DC.
21. Murray F.J. A human health risk assessment of boron (boric acid and borax) in drinking water. Regul Toxicol. 22:1995;221-230.
22. O'Flaherty E.J. Pharmacokinetic, pharmacodynamics, and prediction of developmental abnormalities. Reprod Toxicol. 105:1997;251-266.
23. Roberts SP. Subpopulation risk: interaction of development and genetics. In: ILSI, editor. Similarities and differences between children and adults: implications for risk assessment. Washington, DC: ILSI Press, 1992. p. 11-5.
24. Kacew S. General principles in pharmacology and toxicology applicable to children. In: ISLI, editor. Similarities and differences between children and adults: implications for risk assessment. Washington, DC: ILSI Press, 1992. p. 24-34.
25. Foster P.M.D., Lamb J.C. Introduction in physiology and toxicology of male reproduction. 1988;Academic Press, Boston.
26. Endocrine disruptor screening program statement of policy . Fed Reg. 63:1998d;71542-71568.
27. Ashby J. The value and limitations of short-term genotoxicity assays and the inadequacy of current cancer bioassay chemical selection criteria. Ann NY Acad Sci. 534:1988;133-138.
28. Brown L.P., Ashby J. Correlation between bioassay dose-level, mutagenicity to Salmonella, chemical structure and sites of carcinogenesis among 226 chemicals evaluated for carcinogenicity by the US NTP. Mutat Res. 244:1990;67-76.
29. Barrett J.C., Shelby M.D. Mechanisms of human carcinogens. Prog Clin Bio Res. 374:1992;514-534.
30. Huff J. Issues and controversies surrounding qualitative strategies for identifying and forecasting cancer causing agents in the human environment. Pharmacol Toxicol. 72:1992;12-27.
31. Huff J.E., McConnell E.E., et al. Carcinogenesis studies results of 398 experiments on 104 chemicals from the U.S. National Toxicology Program . Ann NY Acad Sci. 534:1988;1-30.
32. Lamb J.C. Introduction to exposures to endocrine-active substances in the human diet. Dunaif G.E., Olin S.S., Scimeca J., et al. Human diet and endocrine modulation estrogenic and androgenic effects . 1998;220-228 ILSI Press, Washington, DC.
33. Lamb J.C. Can today's risk assessment paradigms deal with endocrine active chemicals? Risk Policy Report. 30:1997;32-35.
34. Kimmel C.A. Approaches to evaluating reproductive hazards and risks. Environ Health Toxicol. 101:1993;137-143.
35. Schwetz B.A., Harris M.W. Developmental toxicology status of the fields and contribution of the National Toxicology Program . Environ Health Perspect. 100:1993;269-282.
36. McLachlan J.A., Newbold R.R., et al. Transplacental toxicology prenatal factors influencing postnatal fertility . Kimmel C.A., Buelke-Sam J. Developmental toxicologoy. 1981;Raven Press, New York.
37. Organisation for Economic Co-operation, and Development (OECD). Screening Information Data Set Manual of the OECD Programme on the Co-operative Investigation of High Production Volume Chemicals. OECD Secretariat, 1997.
38. Organisation for Economic Co-operation, and Development (OECD). Two-Generation Reproduction Toxicity Study. Organisation for Economic Co-operation and Development, 1983b.
39. Organisation for Economic Co-operation, and Development (OECD). One-Generation Reproduction Toxicity Study. Organisation for Economic Co-operation and Development, 1983a.
40. Kimmel C.A., Schwetz B.A. Evolution and progress in safety assessment for developmental and reproductive toxicity. Toxicol Pathol. 25:1997;664-667.
41. Manson LM. Biologic considerations for risk assessment in developmental toxicology. In: Developmental toxicology: mechanisms and risk (Banbury Report 26). New York: Cold Spring Harbor Laboratories, 1987. p. 307-21.
42. Frankos V.H. FDA perspectives on the use of teratology data for human risk assessment. Fundam App Toxicol. 5:1985;615.
43. Schardein J.L., Schwetz B.A., Kenel M.F. Species sensitivities and prediction of teratogenic potential. Environ Health Perspect. 61:1985;55.
44. Makris S, Raffael K, et al. A retrospective analysis of 12 developmental nuerotoxicity studies submitted to the US EPA Office of Prevention, Pesticides, and Toxic Substances (OPPTS), 1998.
45. Levine T.E., Butcher R.E. Workshop on the qualitative and quantitative comparability of human and animal developmental neurotoxicity, work group IV report triggers for developmental neurotoxicity . Neurotoxicol Teratol. 12:1990;281-284.
46. Guidelines for neurotoxicity risk assessment. 1998a;EPA, Washington, DC.
47. Health effects test guidelines OPPTS 870.6300. Developmental neurotoxicity study. 1998b;EPA, Washington, DC.
48. Goldey E.S., Tilson H.A., et al. Implications of the use of the neonatal birth weight growth, viability, and survival data for predicting developmental neurotoxicity a survey of the literature . Neurotox Teratol. 17:1995;313-332.
49. Slikker W. Principles of developmental neurotoxicology. NeuroToxicology. 15:1994;11-16.
50. Reiter L. Neurotoxicolgy in regulation and risk assessment. Dev Pharmacol Ther. 10:1987;354-368.
51. Christian M.S. A critical review of multigeneration studies. J Am Coll Toxicol. 5:1986;161-180.
52. Bern H.A. Diethylstilbestrol (DES) Syndrome. Present status of animal and human studies. Nandi S., Li S.A., Li J.J. Hormonal carcinogenesis. 1992;Springer-Verlag, New York.
53. Mittendorf R. Teratogen update: carcinogenesis and teratogenesis associated with exposure to diethylstilbestrol (DES) in utero. 1995;51:435-45.
54. Palmer A.K. Regulatory requirements for reproductive toxicology theory and practice . Kimmel C.A., Buelke-Sam J. Developmental toxicology. 1986;233-258 Raven Press, New York.
55. Lamb J.C. Design and use of multigenerational breeding studies for identification of reproductive toxicants. Working P.K. Toxicology of the male and female reproductive systems. 1989;131-155 Hemisphere Publishing, New York.
56. Chapin R.E., Morrissey R.E., et al. Are mouse strains differentially susceptible to the reproductive toxicity of ethylene glycol monomethyl ether? A study of three strains. Fundam Appl Toxicol. 21:1993;8-14.
57. Chapin R.E., Sloane R.A. Reproductive assessment by continuous breeding evolving study design and summaries of 90 studies . Environ Health Perspect. 105:1997;199-205.
58. Gulati D.K., Hope E., et al. Reproductive toxicity assessment by continuous breeding in Sprague-Dawley rats a comparison of two study designs . Fundam Appl Toxicol. 17:1991;270-279.
59. Mylchreest ER, Cattley RC, et al. Male reproductive tract malformations in rats following gestation and lactational exposure to di (n-butyl) phthalate: an antiandrogenic mechanism? 1998;43:47-60.
60. Wine R.N., Li L.H., et al. Reproductive Toxicity of Di-n-butylphthalate in a Continuous Breeding Protocol in Sprague-Dawley Rats. Environ Health Perspect. 105:1997;102-107.
61. Piersma A.H., Verhoef A., Dortant P.M. Evaluation of the OECD 421 reproductive toxicity screening test protocol using butyl benzyl phthalate. Toxicol. 99:1995;191-197.
62. Favor J., et al. International commission for protection against environmental mutagen and carcinogens genetic risk extrapolation from animal data to human disease (Taskgroup Report No. 00101) . Mutat Res. 330:1995;23-24.
63. Lohman P.H.M., Mendelsohn M.L., et al. A method for comparing and combining short-term genotoxicity test data the basic system . Mutat Res. 266:1992;7-25.
64. Moore J.A. Carcinogen testing fact or fallacy . Cancer. 62:1988;1688-1690.
65. Ashby J. The value and limitations of short-term genotoxicity assays and the inadequacy of current cancer bioassay chemical selection criteria. Prog Clin Bio Res. 209B:1986;111-119.
66. th ed. 1996;124-128 National Institutes of Health, Washington, DC.
67. Laval G., Tuyns A.J. Environmental factors in childhood leukemia. Br J Indust Med. 45:1988;843-844.
68. Miller RW, Boice JD. Radiogenic cancer after prenatal or childhood exposure. In: Radiation carcinogenesis. New York: Elsevier Press, 1986. p. 379-86.
69. Ries L.A.G., Kosary C.L., Hankey B.F., Miller B.A., Harras A., Edwards B.K. SEER Cancer statistics Review 1973-1994 (NIH Pub. No. 97-2789). 1997;National Cancer Institute, Bethesda, MD.
70. Smith M.A., Freidlin B., Ries L.A.G., Simon R. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Instit. 90:1998;1269-1277.
71. Linet M.S., Ries L.A.G., Smith M.A., Tarone R.E., Devesa S.S. Cancer surveillance series recent trends in childhood cancer incidence and mortality in the United States . J Natl Cancer Instit. 91:1999;1051-1058.
72. Black W. Increasing incidence of childhood primary malignant brain tumors enigma or no-brainer? J Natl Cancer Instit. 90:1998;1249-1251.
73. Rice JM. Effects of prenatal exposure to chemical carcinogens and methods for their detection. Dev Toxicol 1981.
74. Infante P.F. Use of rodent carcinogenicity test results for determining potential cancer risk to humans. Environ Health Perspect. 101:1993;143-148.
75. Haseman J.K., Tharrington E.C., et al. Comparison of site-specific and overall tumor incidence analyses for 81 recent national toxicology program carcinogenicity studies. Regul Toxicol Pharmacol. 6:1986;155-170.
76. Haseman J.K., Huff J.E., et al. Comparative results of 327 chemical carcinogenicity studies. Environ Health Perspect. 74:1987;229-235.
77. Rall D.P. Can laboratory animal carcinogenicity studies predict cancer in exposed children? Environ Health Perspect. 103:1995;173-175.
78. Krewski D., Gaylor D.W., et al. An overview of the report correlation between carcinogenic potency and the maximum tolerated dose: implication for risk assessment . Risk Analysis. 13:1993;383-398.
79. Nielsen P.A. Chemical carcinogens in the environment risk assessment for the environment . Pharmacol Toxicol. 72:1993;46-50.
80. Dybing E. Predictability of human carcinogenicity from animal studies. Regul Toxicol Pharmacol. 6:1986;399-415.
81. Hoel D.G., Haseman J.K., et al. The impact of toxicity on carcinogenicity studies implications for risk assessment . Carcinogenesis. 9:1988;2045-2052.
82. Chacko M., Bhide S.V. Carcinogenicity, perinatal carcinogenicity and teratogenicity of low dose metronidazole (MNZ) in Swiss mice. J Cancer Res Clin Oncol. 112:1986;135-140.
83. Thapa P.B., Whitlock J.A., et al. Prenatal exposure to metronidazole and risk of childhood cancer. Cancer. 83:1998;1461-1468.
84. McConnell E.E. Comparative response in carcinogenesis bioassay as a function of age at first exposure. Guzelian P.S., Henry C.J., Olin S.S. Similarities and differences between children & adults implications for risk assessment . 1992;66-78 ISLI Press, Washington, DC.